Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG study S0003

Journal of Clinical Oncology

Volumn 26, Issue 29, 2008, Pages 4771-4776

  Mack, Philip C ^a   Redman, Mary W ^a   Chansky, Kari ^a   Williamson, Stephen K ^a   Farneth, Nichole C ^a   Lara Jr , Primo N ^a   Franklin, Wilbur A ^a   Le, Quynh Thu ^a   Crowley, John J ^a   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; OSTEOPONTIN; PACLITAXEL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TIRAPAZAMINE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAZARD RATIO; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; OSTEOPONTIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIAZINES; TUMOR MARKERS, BIOLOGICAL;

EID: 54249152439     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.0662     Document Type: Article

References (54)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15-36, 2001
2. Armstrong JG: Tumors of the lung and mediastinum, in Leibel SA, Phillips TL (eds): Textbook of Radiation Oncology (vol 1). Philadelphia, PA, W.B. Saunders Company, 1998, pp 567-600
3. American Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer: Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15:2996-3018, 1997
4. Belani CP: Single agents in the second-line treatment of non-small cell lung cancer. Semin Oncol 25:10-14, 1998
5. Gandara DR, Lara PN, Lau DH, et al: Molecular-clinical correlative studies in non-small cell lung cancer: Application of a three-tiered approach. Lung Cancer 34:S75-S80, 2001 (suppl 3)
6. Rodrigues LR, Teixeira JA, Schmitt FL, et al: The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomarkers Prev 16:1087-1097, 2007
7. Chakraborty G, Jain S, Behera R, et al: The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. Curr Mol Med 6:819-830, 2006
8. Hu DD, Lin EC, Kovach NL, et al: A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem 270:26232-26238, 1995
9. Katagiri YU, Sleeman J, Fujii H, et al: CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 59:219-226, 1999
10. Liaw L, Skinner MP, Raines EW, et al: The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins: Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 95:713-724, 1995
11. Senger DR, Perruzzi CA, Papadopoulos A: Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 9:1291-1299, 1989
12. Chambers AF, Behrend EI, Wilson SM, et al: Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Res 12:43-47, 1992
13. Oates AJ, Barraclough R, Rudland PS: The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 13:97-104, 1996
14. Tuck AB, Arsenault DM, O'Malley FP, et al: Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 18:4237-4246, 1999
15. Le QT, Kong C, Lavori PW, et al: Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 69:167-175, 2007
16. Le QT, Sutphin PD, Raychaudhuri S, et al: Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9:59-67, 2003
17. Ramankulov A, Lein M, Kristiansen G, et al: Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol 133:643-652, 2007
18. Ramankulov A, Lein M, Kristiansen G, et al: Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 67:330-340, 2007
19. Wu CY, Wu MS, Chiang EP, et al: Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 56:782-789, 2007
20. Petrik D, Lavori PW, Cao H, et al: Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol 24:5291-5297, 2006
21. Bramwell VH, Doig GS, Tuck AB, et al: Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12:3337-3343, 2006
22. Shimada Y, Watanabe G, Kawamura J, et al: Clinical significance of osteopontin in esophageal squamous cell carcinoma: Comparison with common tumor markers. Oncology 68:285-292, 2005
23. Chambers AF, Wilson SM, Kerkvliet N, et al: Osteopontin expression in lung cancer. Lung Cancer 15:311-323, 1996
24. Zhang J, Takahashi K, Takahashi F, et al: Differential osteopontin expression in lung cancer. Cancer Lett 171:215-222, 2001
25. Hu Z, Lin D, Yuan J, et al: Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11:4646-4652, 2005
26. Schneider S, Yochim J, Brabender J, et al: Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 10:1588-1596, 2004
27. Shijubo N, Uede T, Kon S, et al: Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. Am J Respir Crit Care Med 160:1269-1273, 1999
28. Boldrini L, Donati V, Dell'Omodarme M, et al: Prognostic significance of osteopontin expression in early-stage non-small-cell lung cancer. Br J Cancer 93:453-457, 2005
29. Le QT, Chen E, Salim A, et al: An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 12:1507-1514, 2006
30. Chang YS, Kim HJ, Chang J, et al: Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 57:373-380, 2007
31. Pass HI, Lott D, Lonardo F, et al: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353:1564-1573, 2005
32. Williamson SK, Crowley JJ, Lara PN Jr, et al: Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 23:9097-9104, 2005
33. Cappuzzo F, Hirsch FR, Rossi E, et al: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655, 2005
34. Koong AC, Mehta VK, Le QT, et al: Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 48:919-922, 2000
35. Dehdashti F, Mintun MA, Lewis JS, et al: In vivo assessment of tumor hypoxia in lung cancer with (60)Cu-ATSM. Eur J Nucl Med Mol Imaging 30:844-850, 2003
36. Urtasun RC, Parliament MB, McEwan AJ, et al: Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside. Br J Cancer Suppl 27:S209-S212, 1996
37. Choi KS, Bae MK, Jeong JW, et al: Hypoxia-induced angiogenesis during carcinogenesis. J Biochem Mol Biol 36:120-127, 2003
38. Shijubo N, Kojima H, Nagata M, et al: Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech 60:186-198, 2003
39. Okunieff P, Ding I, Vaupel P, et al: Evidence for and against hypoxia as the primary cause of tumor aggressiveness. Adv Exp Med Biol 510:69-75, 2003
40. Graeber TG, Osmanian C, Jacks T, et al: Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88-91, 1996
41. Grau C, Overgaard J: Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 13:301-309, 1988
42. Semenza GL: Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 41:79-83, 2002
43. Koong AC, Denko NC, Hudson KM, et al: Candidate genes for the hypoxic tumor phenotype. Cancer Res 60:883-887, 2000
44. Brizel DM, Sibley GS, Prosnitz LR, et al: Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 38:285-289, 1997
45. Gandara DR, Lara PN Jr, Goldberg Z, et al: Tirapazamine: Prototype for a novel class of therapeutic agents targeting tumor hypoxia. Semin Oncol 29:102-109, 2002
46. Brown JM, Siim BG: Hypoxia-specific cytotoxins in cancer therapy. Semin Radiat Oncol 6:22-36, 1996
47. Dorie MJ, Brown JM: Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 39:361-366, 1997
48. Zeman EM, Brown JM, Lemmon MJ, et al: SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12:1239-1242, 1986
49. von Pawel J, von Roemeling R, Gatzemeier U, et al: Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group - Cisplatin Tirapazamine in Subjects With Advanced Previously Untreated Non-Small-Cell Lung Tumors. J Clin Oncol 18:1351-1359, 2000
50. Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature 411:375-379, 2001
51. Murdoch C, Giannoudis A, Lewis CE: Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104:2224-2234, 2004
52. Murdoch C, Muthana M, Lewis CE: Hypoxia regulates macrophage functions in inflammation. J Immunol 175:6257-6263, 2005
53. Dirkx AE, Oude Egbrink MG, Wagstaff J, et al: Monocyte/macrophage infiltration in tumors: Modulators of angiogenesis. J Leukoc Biol 80:1183-1196, 2006
54. Cheng J, Huo DH, Kuang DM, et al: Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells. Cancer Res 67:5141-5147, 2007